ADReCS

Pharmaceutical Information

Drug Name	Saxagliptin
Drug ID	BADD_D01992
Description	Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Indications and Usage	Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
Marketing Status	approved
ATC Code	A10BH03
DrugBank ID	DB06335
KEGG ID	D08996
MeSH ID	C502994
PubChem ID	11235729
TTD Drug ID	D0K9MY
NDC Product Code	50193-4212; 0310-6100; 0310-6105; 11722-078; 0310-7100; 50370-0030; 55154-6931; 0310-7105
UNII	9GB927LAJW
Synonyms	saxagliptin \| 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate \| Onglyza \| BMS 477118 \| BMS477118 \| BMS-477118

Chemical Information

Molecular Formula	C18H25N3O2
CAS Registry Number	361442-04-8
SMILES	C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Hypokalaemia	14.05.03.002	0.000491%
Immune system disorder	10.02.01.001	-	-	-
Infection	11.01.08.002	-	-	-
Interstitial lung disease	10.02.01.033; 22.01.02.003	0.000491%		-
Intestinal obstruction	07.13.01.002	0.000327%		-
Ketoacidosis	14.01.01.008	0.000327%		-
Lactic acidosis	14.01.01.002	0.000491%		-
Liver disorder	09.01.08.001	0.000720%		-
Loss of consciousness	17.02.04.004	0.000720%		-
Lymphocyte count decreased	13.01.06.006	-	-
Lymphoma	01.12.01.001; 16.20.01.001	0.000327%		-
Lymphopenia	01.02.02.002	-	-	-
Medullary thyroid cancer	05.02.05.007; 16.24.03.004	0.000655%		-
Melaena	07.12.02.004; 24.07.02.013	0.000327%		-
Metastases to liver	09.04.02.004; 16.22.02.001	0.000327%		-
Multiple fractures	12.04.02.009; 15.08.02.005	-	-	-
Myalgia	15.05.02.001	0.001277%
Myocardial ischaemia	02.02.02.008; 24.04.04.010	0.000327%		-
Nasopharyngitis	11.01.13.002; 22.07.03.002	-	-	-
Nausea	07.01.07.001	-	-
Neoplasm malignant	16.16.01.001	0.000491%		-
Oedema peripheral	02.05.04.007; 08.01.07.007; 14.05.06.011	0.000720%
Oesophageal carcinoma	07.21.06.001; 16.13.06.001	0.000655%		-
Opportunistic infection	11.01.08.007	-	-	-
Osteoarthritis	15.01.04.001	0.000327%		-
Palpitations	02.11.04.012	0.000327%
Pancreatic carcinoma	07.21.09.002; 16.13.10.001	0.001637%		-
Pancreatitis	07.18.01.001	0.007071%
Pancreatitis acute	07.18.01.002	0.001637%		-
Pemphigoid	10.04.02.002; 23.03.01.004	0.000327%		-

The 3th Page First Pre 3 4 5 Next Last Total 5 Pages